Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Probiotics Yang02/Yang03 for Acne Vulgaris (Randomized Double-Blind Placebo-Controlled Phase 4 Study)
ChiCTR2600117010Phase 4Not yet recruiting
- Sponsor
- Southern Medical University Dermatology Hospital
- Start
- Jan 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Yang02 probiotic in acne vulgaris (4 arms), sponsored by Southern Medical University Dermatology Hospital. Primary endpoint: Percentage change in total lesion count from baseline to Week 12. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
Yang02 probiotic
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on ChiCTR2600117010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117010.